Is Taurolidine a candidate for treatment of rheumatoid arthritis?

OBJECTIVE To study the therapeutic potential of taurolidine (TRD), a derivative of taurine with known anti-inflammatory and anti-proliferative properties, in various experimental models of synovitis. METHODS In vitro: fibroblast-like synoviocytes (RA FLS) isolated from the synovial tissue of patients with rheumatoid arthritis (RA) were cultured in the presence of either TRD or polyvinylpyrrolidine (PVP), the pharmaceutical stabilizer of TRD, which was used as a control. Proliferation of RA FLS and cytokine (IL-6 and IL-8) release were measured. In vivo: (A). The effect of systemic TRD treatment on the development of collagen-induced arthritis (CIA) in female DBA1/J mice was investigated. Mice were treated either with intraperitoneal injections of 1 ml of 2% Taurolin Boehringer Ingelheim (TRD +PVP) or with PVP as placebo. The incidence of arthritis, myeloperoxidase (MPO) activity in periarticular tissue, as well as serum concentration of IgG specific to collagen II (IgG alphaCII) were determined. (B). The effect of intra-articular TRD treatment was studied in rabbits with antigen-induced monoarthritis (AIA). After the induction of AIA of right knees rabbits were treated either with intra-articular injections of 0.5 ml of 2% Taurolin or 0.5ml PVP ( placebo). The animals were examined for clinical signs of arthritis and diameter of joints was measured. After termination of the experiment, the arthritic knees were examined and histopathology of the joints was assessed. In addition, serum amyloid A (SAA) concentration was measured. RESULTS n vitro: TRD exerted cytotoxic effect on RA FLS when applied at concentrations >100 microM. TRD at non-cytotoxic concentrations, inhibited PDGF-triggered RA FLS proliferation, reduced IL-1beta - stimulated production of IL-6 and slightly decreased intracellular content of IL-8. In vivo: (A). Intraperitoneal treatment with Taurolin significantly reduced the incidence (30%) of CIA when compared to the control mice (79%). However, Taurolin failed to control the development of CIA in mice with high serum level of IgG alphaCII (>1000 U).(B). Intra-articular application of 2% Taurolin resulted in amelioration of AIA in all treated rabbits (reduced diameter of arthritic joints and smaller rise of SAA level as compared to the control animals). Histopathologic evaluation revealed pannus formation in both groups and extensive necrotic lesions of synovial tissue treated with TRD, suggesting synoviorthesis-like effect. CONCLUSION Results from AIA and from in vitro RA FLS studies suggest that intra-articular administration of TRD could be used as a "pharmacological scalpel" to remove the inflamed synovium. Our data confirmed anti-inflammatory and anti-proliferative properties of TRD in all experimental models encouraging further studies which should evaluate its therapeutic potential in RA.

[1]  G. Panayi,et al.  Treatment of murine collagen-induced arthritis by the stress protein BiP via interleukin-4-producing regulatory T cells: a novel function for an ancient protein. , 2006, Arthritis and rheumatism.

[2]  C. Braumann,et al.  Taurolidine–a new drug with anti-tumor and anti-angiogenic effects , 2005, Anti-cancer drugs.

[3]  M. Kokubun,et al.  Serum amyloid A (SAA) concentration varies among rheumatoid arthritis patients estimated by SAA/CRP ratio. , 2005, Clinica chimica acta; international journal of clinical chemistry.

[4]  H. Schumacher,et al.  Elimination of rheumatoid synovium in situ using a Fas ligand 'gene scalpel' , 2005, Arthritis research & therapy.

[5]  A. Tarkowski,et al.  Inhibition of septic arthritis by local administration of taurine chloramine, a product of activated neutrophils. , 2005, The Journal of rheumatology.

[6]  R. Holmdahl,et al.  Humoral immune response to citrullinated collagen type II determinants in early rheumatoid arthritis , 2005, European journal of immunology.

[7]  K. Ishii,et al.  Suppressive oligonucleotides protect against collagen-induced arthritis in mice. , 2004, Arthritis and rheumatism.

[8]  P. Robbins,et al.  TNF receptor gene therapy results in suppression of IgG2a anticollagen antibody in collagen induced arthritis , 2003, Annals of the rheumatic diseases.

[9]  A. Falus,et al.  Elevated levels of synovial fluid antibodies reactive with the small proteoglycans biglycan and decorin in patients with rheumatoid arthritis or other joint diseases. , 2003, Rheumatology.

[10]  Kutty Selva Nandakumar,et al.  Epitope-specific recognition of type II collagen by rheumatoid arthritis antibodies is shared with recognition by antibodies that are arthritogenic in collagen-induced arthritis in the mouse. , 2002, Arthritis and rheumatism.

[11]  P. Calabresi,et al.  Taurolidine: preclinical evaluation of a novel, highly selective, agent for bone marrow purging , 2002, Bone Marrow Transplantation.

[12]  P. Calabresi,et al.  Taurolidine: cytotoxic and mechanistic evaluation of a novel antineoplastic agent. , 2001, Cancer research.

[13]  W. Maśliński,et al.  The mechanism of taurine chloramine inhibition of cytokine (interleukin-6, interleukin-8) production by rheumatoid arthritis fibroblast-like synoviocytes. , 2000, Arthritis and rheumatism.

[14]  H. Redmond,et al.  Taurolidine Inhibits Tumor Cell Growth In Vitro and In Vivo , 2000, Annals of Surgical Oncology.

[15]  G. Eliopoulos,et al.  Activities of Taurolidine In Vitro and in Experimental Enterococcal Endocarditis , 2000, Antimicrobial Agents and Chemotherapy.

[16]  W. Maśliński,et al.  Taurine chloramine inhibition of cell proliferation and cytokine production by rheumatoid arthritis fibroblast-like synoviocytes. , 1999, Arthritis and rheumatism.

[17]  E. Keystone,et al.  Amelioration of antigen-induced arthritis in rabbits by induction of apoptosis of inflammatory cells with local application of transdermal photodynamic therapy. , 1998, Arthritis and rheumatism.

[18]  A. Kang,et al.  Autoantibodies to murine type II collagen in collagen-induced arthritis: a comparison of susceptible and nonsusceptible strains. , 1996, Journal of immunology.

[19]  G. Firestein.  Invasive fibroblast-like synoviocytes in rheumatoid arthritis. Passive responders or transformed aggressors? , 1996, Arthritis and rheumatism.

[20]  J. Bereta,et al.  Taurine chioramine , a product of activated neutrophils , inhibits in vitro the generation of nitric oxide and other macrophage inflammatory mediators , 2005 .

[21]  H. Redmond,et al.  Taurolidine, an antilipopolysaccharide agent, has immunoregulatory properties that are mediated by the amino acid taurine , 1995, Journal of leukocyte biology.

[22]  M. Liang,et al.  The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. , 1988, Arthritis and rheumatism.

[23]  M. K. Browne,et al.  Taurolin, a new chemotherapeutic agent. , 1976, The Journal of applied bacteriology.

[24]  P. Schmittenbecher.  Peritoneal taurolidine lavage in children with localized peritonitis due to appendicitis, A. Schneider, U. Sack, K. Rothe, in: Pediatr Surg Int, 21. (2005 (June)), 445 , 2006 .

[25]  M. Koprowski,et al.  Is there a role of taurine bromamine in inflammation? Interactive effects with nitrite and hydrogen peroxide , 2004, Inflammation Research.

[26]  Richard O. Williams.  Collagen-induced arthritis as a model for rheumatoid arthritis. , 2004, Methods in molecular medicine.

[27]  E. Park,et al.  Taurine and Its Chloramine: Modulators of Immunity , 2004, Neurochemical Research.

[28]  E. Kontny,et al.  Effect of taurine chloramine, the product of activated neutrophils, on the development of collagen-induced arthritis in DBA 1/J mice , 2002, Amino Acids.